ClinicalTrials.gov record NCT05809323
Marfan Syndrome Moderate Exercise Trial II
Clinical Trial On The Effects Of Moderate Physical Activity On Health And Well-Being In Adolescents And Young Adults With Marfan Syndrome
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This randomized trial enrolls adolescents and young people (ages 10–25) with Marfan syndrome to compare a supervised moderate exercise program with continuing usual activity. About 50 participants are assigned (unequal allocation) to exercise or control, complete baseline cardiovascular, musculoskeletal, and mental-health assessments, and are reassessed after the intervention period. The exercise program is taught and supervised by a physical therapist, uses activity tracking and weekly phone check-ins, and lasts about 12 weeks before follow-up testing. After the comparison period, participants in the control group are offered the same exercise program.
What it is studying. The study tests whether a 12-week, physical-therapist–led moderate dynamic exercise program changes measures of heart and aorta structure and function (for example, maximal oxygen uptake and aortic strain), physical fitness, and mental-health/quality-of-life measures compared with usual activity in 10–25-year-olds with Marfan syndrome.
What the researchers hope to learn. To learn whether a supervised moderate exercise program affects maximal oxygen uptake, blood pressure, aortic stiffness and dimensions, ventricular strain and volumes, and measures of physical function and mental health in adolescents and young adults with Marfan syndrome.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
Marfan syndrome (MFS) is a distinctive connective tissue disorder that affects multiple organ systems including the heart, bones, ligaments, and eyes, and is associated with significant risk of aortic dissection. Given limited evidence from in-vitro studies, and theoretical concerns, the majority of patients with MFS are restricted from certain physical activities. The lack of exercise and deconditioning have detrimental effects including increasing weakness, joint pain, decreased endurance, and depressive symptoms. Given the significant paucity of data currently existing on the effects of exercise in humans with MFS, and the recent, optimistic findings in rodent models, this pilot trial was established to assess the effects of moderated dynamic exercise in adolescents and young adults with MFS.
Interventions being studied
Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.
- Other
- Exercise Intervention Group
- Control Group
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- Male and female patients diagnosed with Marfan syndrome (defined by Ghent criteria and either a pathogenic variant in FBN1 or ectopia lentis)
- Age 10-25 years at enrollment
Exclusion criteria
- History of aortic surgery
- History of spinal surgery with implanted materials that may negatively impact MRI safety or imaging quality.
- Diagnosis of major congenital heart disease (ASD, VSD, bicuspid aortic valve, and mitral valve prolapse will not qualify as exclusion criteria)
- Condition limiting the ability to perform moderate exercise.
- Major concurrent diagnosis that may confound the interpretation of the effect of the proposed intervention on the proposed outcome measures.
- Aortic dilation meeting threshold for prophylactic aortic surgical intervention (>/= 4.5 cm in diameter)
Study description and what participation involves
The study's detailed description, as published on ClinicalTrials.gov.
Show the detailed description from the registry
Marfan syndrome (MFS) is a distinctive connective tissue disorder with clinical phenotypes that affect multiple organ systems including the heart, bones, ligaments, and eyes, and are associated with significant risk of aortic dissection. Given anecdotal reports of aortic dissection, limited evidence from in-vitro studies, and theoretical concerns, the majority of patients with MFS are restricted from certain physical activities, most commonly isometric exercise and contact sports. Published guidelines also suggest restriction from highly dynamic competitive sports. While clinicians may mean to restrict patients only from competitive sports, often children and families interpret this caution as applying to almost all exercise, resulting in a large number of patients with MFS being sedentary. This lack of exercise and deconditioning likely has detrimental effects in increasing weakness and joint pain and decreasing endurance. Depressive symptoms are also not uncommon in patients with these syndromes, and may be triggered or exacerbated by guidance to acutely cease participation in sports at the time of diagnosis. To date, as far as we are aware, there are no published controlled studies on the effects of dynamic exercise on human subjects. In 2017, Mas-Stachurska et al published a study suggesting that a moderate level of dynamic exercise mitigated progressive degradation of the cardiac structures typically seen in MFS in a rodent sample. This study suggests the possibility that the fears surrounding moderate exercise in humans may be unwarranted. In addition, this study suggests that moderate exercise may actually protect the aorta and myocardium, in addition to the numerous other physical and emotional benefits that have been shown to result from consistent exercise. We have unpublished trial results in a pilot study that also suggest benefit to adolecents and young adults. Given the significant paucity of data currently existing on effects of exercise in humans with MFS, and the recent optimistic findings in rodent models, we plan to conduct a randomized control trial of moderate dynamic exercise in adolescents and young adults with MFS. The objective is to:
- Randomize 50 patients with Marfan syndrome from ages 10-25 years to current status and care (controls) versus a moderate dynamic exercise intervention, then 2) allow the control group patients to undergo the exercise intervention.The investigators will then compare outcomes between both the intervention and control groups, and between the baseline and post-intervention states. Specific outcome measures will include cardiovascular assessment: maximal oxygen uptake (max VO2), ambulatory blood pressure, segmental and central aortic stiffness, ventricular mass and volume, and endothelial function, physical assessment by the physical therapist, and quality of life/mental health assessment: health-related quality of life, depression and anxiety screening scales. The hypothesis is that the intervention of a moderate exercise program introduced by a licensed physical therapist will result in improvement in cardiovascular status, muscular health, and mental health without detrimental effects on the aortic wall.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
Participants will have baseline and end-of-study assessments of heart and blood-vessel status, exercise capacity, physical function, and mental-health/quality-of-life questionnaires. The exercise group receives education, demonstrations and supervised sessions with a physical therapist to reach and sustain moderate-intensity activity (goal at least 150 minutes/week), uses an activity tracker, and gets weekly phone calls for safety and guidance over a 12-week period; the control group continues usual activity and uses the tracker. Central tests include an exercise stress test (to measure maximal VO2), cardiac MRI measures (aorta and ventricles), ambulatory blood pressure monitoring, physical-therapy assessments, and repeated questionnaires. All participants return for re-assessment after the intervention period.
How the study is structured. Interventional, randomized, non-blinded, parallel-group trial. Participants are randomly assigned (with an unequal allocation favoring the exercise arm) to either a supervised moderate exercise program or to continue baseline activity. The exercise group receives instruction, supervised sessions until they reach moderate intensity, an activity tracker, and weekly phone follow-up; both groups have baseline and post-intervention testing including exercise testing, blood pressure monitoring, cardiac MRI measures, and questionnaires. The control group continues usual activities and returns for the same reassessments after the study period.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on Marfan syndrome
Important dates
- Study start
- Sep 1, 2023
- Primary completion
- Jul 1, 2025 (estimated)
- Study completion
- Jul 1, 2027 (estimated)
- Target enrollment
- 50 participants (estimated)
- Last updated on registry
- Jan 24, 2024
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- Baylor College of Medicine
- Principal investigator
- Shaine Morris, Associate Professor, Pediatrics-Cardiology
Baylor College of Medicine - Collaborators
- Southern Star Research
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- Shaine A Morris, MD, MPH 📞 832-826-5692 ✉ shainem@bcm.edu
- Jennifer Bogardus, PT, MPT, PhD 📞 713-794-2070 ✉ jennifer.bogardus@utah.edu
Participating sites (1)
- Texas Children's HospitalRecruiting
Houston, Texas, 77030 · United States
- Shaine A Morris, MD MPH · 832-826-5682 · shainem@bcm.edu
- Jennifer Bogardus, PT, MPT, PhD · 713-794-2070 · jbogardus@twu.edu
Terms used on this page · explanations by MedicalUpdates.ai
- enrollment
- The number of participants a study plans to include, or has included. 'Estimated' means the planned number; 'actual' means the number who joined.
- MRI
- A scan that uses magnets and radio waves, not X-rays, to make detailed pictures of the inside of the body. Some implants and metal objects mean a person cannot have one.
- exclusion criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
- outcome measures
- Something the study measures to judge its results, such as a symptom score, a blood test or survival. Outcomes are grouped as primary, secondary and sometimes exploratory.
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- randomized
- Participants are assigned to the study groups by chance, like a coin toss, rather than chosen by the doctor or the participant. This is done so the groups are comparable.
- control group
- The group the study treatment is compared with. It may receive a placebo, an existing treatment (active comparator), a sham procedure, or no intervention.
- baseline
- Measurements taken at the start of the study, before any study treatment, so that later results can be compared with them.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials